1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
- Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. (
- 2008
- A Randomised Placebo Controlled Study With Melphalan/Prednisone Vs Melphalan/Prednisone/Thalidomide: Quality Of Life And Toxicity (
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma (
- 2004
- Low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma (
- Early response predicts thalidomide efficiency in patients with advanced multiple myeloma (
- Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma (
- 2003
- Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. (
- 2002
- Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor (
- 2000
- Perfusion magnetic resonance imaging of the lung: characterization of pneumonia and chronic obstructive pulmonary disease. A feasibility study (
- A closed-chest pulmonary artery occlusion/reperfusion model in the pig: detection of experimental pulmonary embolism with MR angiography and perfusion MR imaging (